InfuSystem Holdings, Inc. reported 2025 net revenue of $143.4M, up 6% year over year, and adjusted EBITDA of $31.5M, up 25%, with adjusted EBITDA margin of 21.9%.
INFU · InfuSystem Holdings, Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 41%
- Last earnings
- Nov 3, 2026
- Latest filing
- 10-Q · Nov 9
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
For the three months ended September 30, 2026, InfuSystem Holdings, Inc. reported net revenues of $37.6 million, up 3.0%, with Patient Services revenue rising 15.4% and Device Solutions revenue falling 16.6%; gross margin increased to 57.8%.
InfuSystem Holdings, Inc. reported third-quarter net revenues of $37.6 million, up 3.0%, net income of $3.2 million and Adjusted EBITDA of $9.4 million at a 24.9% margin; it reaffirmed 2026 pro-forma revenue growth guidance of 6% to 8%.
InfuSystem Holdings reported revenue of $37.6 million, up 3%, and pro forma growth of 10.2% as wound care rose 112%. Adjusted EBITDA was $9.4 million with a 24.9% margin, and reaffirmed 2026 pro forma growth guidance of 6% to 8%.
InfuSystem Holdings, Inc. postponed third-quarter financial results for the period ended September 30, 2026 while evaluating whether new ERP system implementation costs should be capitalized rather than expensed.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. InfuSystem reported Q2 2026 net revenues of $36.9 million (up 2.6%, or 7.5% pro forma), record Adjusted EBITDA of $8.6 million with margin expansion to 23.4%, driven by strong Patient Services growth, while Device Solutions revenue fell 16.1% on the GE Healthcare restructuring. The company reaffirmed full-year 2026 pro forma revenue growth guidance of 6%–8% and mid-to-low 20%s Adjusted EBITDA margin.
- + Patient Services revenue surged 15.2% YoY, led by Wound Care up 154% on new lymphedema compression offerings.
- + Company reaffirmed full-year 2026 pro forma revenue growth guidance of 6%–8% and mid-to-low 20%s Adjusted EBITDA margin.
- − Device Solutions revenue fell 16.1% YoY to $12.1 million, with biomedical services down 39.4% on the GE Healthcare contract restructuring.
- − Patient Services gross margin contracted 2.4 points to 61.8% on unfavorable mix toward lower-margin Wound Care and higher pump maintenance costs.
- − G&A expenses rose 7.2% to $14.1 million and rose to 38.2% of revenue from 36.5%, driven by higher stock comp, wages, and healthcare inflation.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross margin | 57.8% | the three months ended September 30, 2026 filing | — |
| Net operating lease revenue | 8.15M | the three months ended September 30, 2026 filing | — |
| Patient Services gross margin | 61.5% | the three months ended September 30, 2026 filing | — |
| Purchases of medical equipment | 2.17M | the three months ended September 30, 2026 filing | — |
|
|
|||
| Sales-type lease revenue | 127K | the three months ended September 30, 2026 filing | — |
| Total Number of Shares Purchased | 52,442 | the three months ended September 30, 2026 filing | — |
|
|
|||
| Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | 50,439 | the three months ended September 30, 2026 filing | — |
|
|
|||
| Adjusted EBITDA (non-GAAP) non-GAAP | $9.4M | third quarter 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 24.9% | third quarter 2026 | — |
|
|
|||
| Available borrowing capacity under revolving line of credit | $55M | as of September 30, 2026 | — |
| Available liquidity | $64.1M | as of September 30, 2026 | — |
| Common stock repurchased under share repurchase program | $5M | nine-month period of 2026 | — |
| Device Solutions gross margin | 49.7% | current period (third quarter 2026) | — |
|
|
|||
| Device Solutions net revenue | $11.8M | third quarter of 2026 | — |
|
|
|||
| Net debt (non-GAAP) non-GAAP | $10.6M | as of September 30, 2026 | — |
| Non-GAAP Pro-Forma Net Revenue Growth from Prior Year non-GAAP | 10.2% | third quarter of 2026 | — |
| Operating cash flow | $18.1M | nine-month period ended September 30, 2026 | — |
| Patient Services net revenue | $25.8M | 2026 Third Quarter | +15.4% |
|
|
|||
| Pro-forma revenue growth | 10.2% | 2026 Third Quarter | — |
| Purchases of medical devices | $8.7M | nine-month period of 2026 | — |
| Ratio of net debt to Adjusted EBITDA (non-GAAP) non-GAAP | 0.32 | last four quarters as of September 30, 2026 | — |
| Trailing four quarter Adjusted EBITDA non-GAAP | $33.1M | last four quarters as of September 30, 2026 | — |
| Ratio of Adjusted EBITDA to net debt (non-GAAP) non-GAAP | 0.61 | the last four quarters | — |
| Stock repurchases | $3.5M | the quarter | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INFU
this stock
InfuSystem Holdings, Inc
|
$281.67M | +56.7% | +6.4% | 32.0 | 3.4% |
|
ABT
Abbott Laboratories
|
$179.90B | -17.1% | +5.7% | 38.8 | 1.1% |
|
MDT
Medtronic plc
|
$128.69B | +4.7% | +8.4% | 24.8 | 1.8% |
|
SYK
Stryker Corp
|
$119.19B | -10.9% | +11.2% | 33.3 | 1.7% |
|
BSX
Boston Scientific Corp
|
$62.31B | -54.9% | +12.5% | 18.2 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 9, 2026
- This year
- 24
For the three months ended September 30, 2026, InfuSystem Holdings, Inc. reported net revenues of $37.6 million, up 3.0%, with Patient Services revenue rising 15.4% and Device Solutions revenue falling 16.6%; gross margin increased to 57.8%.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INFU | -4.9% | -0.6% | +57.1% | -0.1% | +56.7% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +0.5% | +5.7% | +62.7% | +5.2% | +51.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.